Takashi Kojima

11.6k total citations · 4 hit papers
231 papers, 5.5k citations indexed

About

Takashi Kojima is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Takashi Kojima has authored 231 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Pulmonary and Respiratory Medicine, 136 papers in Surgery and 115 papers in Oncology. Recurrent topics in Takashi Kojima's work include Esophageal Cancer Research and Treatment (124 papers), Gastric Cancer Management and Outcomes (97 papers) and Cancer Immunotherapy and Biomarkers (58 papers). Takashi Kojima is often cited by papers focused on Esophageal Cancer Research and Treatment (124 papers), Gastric Cancer Management and Outcomes (97 papers) and Cancer Immunotherapy and Biomarkers (58 papers). Takashi Kojima collaborates with scholars based in Japan, United States and South Korea. Takashi Kojima's co-authors include Toshihiko Doi, Atsushi Ohtsu, Ken Kato, Kohei Shitara, Akihito Kawazoe, Hiroki Hara, Takayuki Yoshino, Daisuke Kotani, Takeshi Kuwata and Yasutoshi Kuboki and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Takashi Kojima

223 papers receiving 5.5k citations

Hit Papers

Regorafenib Plus Nivolumab in Patients With Advanced Gast... 2017 2026 2020 2023 2020 2018 2017 2022 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
    2020 567 citations Hiroki Hara, Takashi Kojima et al. Journal of Clinical Oncology profile →
  2. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
    2018 362 citations Takashi Kojima, Ken Kato et al. profile →
  3. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
    2017 292 citations Toshihiro Kudo, Yasuo Hamamoto et al. profile →
  4. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.
    2022 119 citations Ken Kato, Yoshinori Ito et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Takashi Kojima Japan 37 3.2k 2.7k 2.7k 724 596 231 5.5k
Michele Orditura Italy 44 3.4k 1.1× 2.1k 0.8× 1.2k 0.4× 677 0.9× 1.9k 3.2× 181 6.1k
Masahide Ikeguchi Japan 40 1.7k 0.5× 1.8k 0.7× 1.3k 0.5× 677 0.9× 1.4k 2.4× 198 4.6k
Ferdinando De Vita Italy 43 3.4k 1.1× 2.2k 0.8× 1.2k 0.4× 603 0.8× 2.0k 3.3× 207 6.0k
Toshifumi Wakai Japan 44 2.2k 0.7× 2.2k 0.8× 2.6k 1.0× 474 0.7× 1.7k 2.9× 346 6.0k
Michael K. Gibson United States 33 2.7k 0.9× 2.6k 1.0× 2.8k 1.0× 425 0.6× 2.0k 3.3× 155 6.5k
Giandomenico Roviello Italy 33 1.9k 0.6× 2.0k 0.7× 923 0.3× 323 0.4× 1.5k 2.5× 262 4.6k
Tomoki Makino Japan 37 1.3k 0.4× 1.8k 0.7× 2.2k 0.8× 253 0.3× 640 1.1× 269 3.9k
Baki Topal Belgium 40 2.5k 0.8× 2.0k 0.7× 2.3k 0.8× 303 0.4× 1.4k 2.4× 100 5.6k
Vincenzo Catalano Italy 40 3.1k 1.0× 1.6k 0.6× 1.2k 0.4× 353 0.5× 1.4k 2.3× 124 5.1k
Nathan R. Foster United States 38 4.1k 1.3× 1.3k 0.5× 1.1k 0.4× 407 0.6× 1.3k 2.3× 170 6.0k

Countries citing papers authored by Takashi Kojima

Since Specialization
Citations

This map shows the geographic impact of Takashi Kojima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takashi Kojima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takashi Kojima more than expected).

Fields of papers citing papers by Takashi Kojima

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takashi Kojima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takashi Kojima. The network helps show where Takashi Kojima may publish in the future.

Co-authorship network of co-authors of Takashi Kojima

This figure shows the co-authorship network connecting the top 25 collaborators of Takashi Kojima. A scholar is included among the top collaborators of Takashi Kojima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takashi Kojima. Takashi Kojima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yamamoto, Shun, Ken Kato, Hiroyuki Daiko, et al.. (2024). Factors influencing decision-making between surgery and chemoradiotherapy for esophageal carcinoma from the JCOG0502. Future Oncology. 20(36). 2849–2854. 1 indexed citations
3.
Saeki, Koichi, Masaki Nakamura, Hidehiro Hojo, et al.. (2024). Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration. Cancer Immunology Research. 13(3). 353–364. 4 indexed citations
4.
Muto, Manabu, Katsuyuki Sakanaka, Shinya Ohashi, et al.. (2024). Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.. Journal of Clinical Oncology. 42(16_suppl). 4068–4068. 1 indexed citations
5.
6.
Matsuo, Norikazu, Koichi Azuma, Kenta Murotani, et al.. (2023). Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors. Thoracic Cancer. 14(15). 1362–1367. 15 indexed citations
7.
Doi, Toshihiko, Kohei Shitara, Takashi Kojima, et al.. (2022). Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer Science. 114(2). 574–585. 23 indexed citations
8.
Kato, Ken, Yoshinori Ito, Isao Nozaki, et al.. (2021). Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology. 161(6). 1878–1886.e2. 62 indexed citations
9.
Maeda, Yuka, Hisashi Wada, Daisuke Sugiyama, et al.. (2021). Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nature Communications. 12(1). 7280–7280. 29 indexed citations
10.
Miura, Tomofumi, Eriko Satomi, Keita Tagami, et al.. (2021). Dexamethasone 8 mg for Cancer-Related Fatigue in Inpatients with Advanced Cancer Undergoing Palliative Care: A Multicenter Phase II Trial. SHILAP Revista de lepidopterología. 2(1). 316–323. 3 indexed citations
11.
Kato, Ken, Yuichiro� Doki, Takashi Ura, et al.. (2020). Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Cancer Science. 111(5). 1676–1684. 23 indexed citations
12.
Kubota, Yohei, Akihito Kawazoe, Akinori Sasaki, et al.. (2020). The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer. Clinical Cancer Research. 26(14). 3784–3790. 54 indexed citations
13.
Sasaki, Akinori, Akihito Kawazoe, Saori Mishima, et al.. (2020). Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open. 5(4). e000775–e000775. 30 indexed citations
14.
Kuboki, Yasutoshi, Yoshikatsu Koga, Takashi Kojima, et al.. (2019). U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer. Molecular Cancer Therapeutics. 18(11). 2043–2050. 65 indexed citations
15.
Sasaki, Akinori, Yoshiaki Nakamura, Saori Mishima, et al.. (2019). Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer. 22(4). 793–802. 114 indexed citations
16.
Yano, Tomonori, Ken Hatogai, Takashi Kojima, et al.. (2017). Salvage endoscopic resection (ER) after chemoradiotherapy for esophageal squamous cell carcinoma: What are the risk factors for recurrence after salvage ER?. Digestive Endoscopy. 30(3). 338–346. 15 indexed citations
17.
Okuno, Tatsuya, Masashi Wakabayashi, Ken Kato, et al.. (2017). Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). International Journal of Clinical Oncology. 22(6). 1042–1049. 31 indexed citations
18.
Kurose, Koji, Yoshihiro Ohue, Hisashi Wada, et al.. (2015). Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Clinical Cancer Research. 21(19). 4327–4336. 179 indexed citations
19.
Kamei, Hideo, et al.. (1998). Effect of Gold on Survival of Tumor-Bearing Mice. Cancer Biotherapy and Radiopharmaceuticals. 13(5). 403–406. 15 indexed citations
20.
Kamei, Hideo, et al.. (1997). Tumor Cell Growth-Inhibiting Effect of Melanoidins Extracted from Miso and Soy Sauce. Cancer Biotherapy and Radiopharmaceuticals. 12(6). 405–409. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michele Orditura Breakdown of academic impact, for papers by Masahide Ikeguchi Breakdown of academic impact, for papers by Ferdinando De Vita Breakdown of academic impact, for papers by Toshifumi Wakai Breakdown of academic impact, for papers by Michael K. Gibson Breakdown of academic impact, for papers by Giandomenico Roviello Breakdown of academic impact, for papers by Tomoki Makino Breakdown of academic impact, for papers by Baki Topal Breakdown of academic impact, for papers by Vincenzo Catalano Breakdown of academic impact, for papers by Nathan R. Foster
Rankless by CCL
2026